Stocktoria
OnKure Therapeutics, Inc. OKUR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-04-09
OnKure Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — |
| R&D expense | $48.3M | $43.8M | $32.1M | $37.7M | $28.2M |
| Operating income | -$63.0M | -$54.4M | -$36.9M | -$53.8M | -$39.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.5M | -$52.7M | -$35.3M | -$52.0M | -$39.8M |
| EPS (diluted) | $-4.40 | $-15.28 | $-124.41 | $-2.12 | $-2.19 |
| Operating cash flow | -$51.8M | -$51.1M | -$34.5M | -$47.4M | -$38.0M |
| Free cash flow | -$51.9M | -$51.2M | -$34.8M | -$47.7M | -$38.2M |
| Cash & equivalents | $59.0M | $110.8M | $29.9M | $19.9M | $124.7M |
| Total assets | $62.1M | $114.9M | $35.7M | $108.2M | $154.0M |
| Total liabilities | $5.9M | $11.1M | $7.8M | $8.2M | $6.8M |
| Shareholders' equity | $56.2M | $103.8M | -$101.8M | -$54.4M | $147.2M |
Source: SEC EDGAR filings · CIK 0001637715 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.